Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed
in new markets - Fresenius Medical Care
for further growth - Fresenius Kabi
for better health - Fresenius Helios
for greater efficiency - Fresenius Vamed
close

Seizing opportunities > in new markets

Asia is an important growth market for Fresenius Medical Care. Approximately 620,000 patients with chronic kidney failure are currently being treated in this region, and every year this number increases by about 10 to 11%. We will continue to take advantage of this growth potential. The significant demand for dialysis services offers substantial opportunities to expand our network of clinics in the Asian countries.

In 2008, Fresenius Medical Care achieved sales of US$ 606 million in the Asia-Pacific region. Our goal is to continue our strong organic growth and to increase sales to more than US$ 800 million in constant currency by 2010.

FRESENIUS MEDICAL CARE IN ASIA
  2008 2007 Change
Sales (in million US$) 606 541 12%
Employees (December 31) 3,558 3,095 15%
Dialysis patients (December 31) 9,158 7,789 18%
Dialysis treatments (million) 1.34 1.21 11%
Dialysis clinics (December 31) 125 105 19%
 

READ MORE ABOUT FRESENIUS MEDICAL CARE >>

close
in new markets - Fresenius Medical Care
close

Seizing opportunities > for further growth

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.

At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES
  2008
Sales US$ 777 million
EBITDA, adjusted* US$ 317 million
EBITDA margin, adjusted* 40.8%
Employees (December 31, full-time equivalent) 1,487
Production facilities 3
Produkte >100
Number of products ~17%
 

READ MORE ABOUT FRESENIUS KABI >>

close
for further growth - Fresenius Kabi
close

Seizing opportunities > for better health

At Fresenius Helios, our commitment is to provide the highest medical quality and care. We aim to offer advanced and proven best-in-class diagnosis and treatment methods for the benefit of our patients. We continuously invest in high-quality, state-of-the-art medicine, and aim to measure and improve the quality of medical care.

Our target ist that our quality indicators should be better than the German average. With a mortality rate of SMR < 1, this was accomplished, among others, for major illnesses shown below.

HELIOS QUALITY INDICATORS
Indications/
standardized mortality rate (SMR)*
2008
SMR
2007
SMR
Acute myocardial infarction 0.73 0.79
Heart failure 0.73 0.85
Stroke 0.83 1.01
Acute cerebral infarction 0.81 0.99
Pneumonia 0.71 0.85
 

READ MORE ABOUT FRESENIUS HELIOS >> 

close
for better health - Fresenius Helios
close

Seizing opportunities > for greater efficiency

Fresenius Vamed is a leading international provider of services in the planning, construction, and management of health care facilities. Our complete value chain and our more than 25 years of international experience are key to providing effective support for hospitals at every stage of their life cycle, and thus contributing towards their successful operating performance. For us, each project is another opportunity to prove our competence.

Hospitals face the dual challenge of increasing efficiency and reducing expenditure. We support hospitals by offering comprehensive process know-how and by taking over medical-technical services and management functions.

VAMED SERVICES
   
Service contracts* for   140 clinics
  ~ 50,000 beds
among others:  
Vienna General Hospital and University Clinics (AKH) ~ 2,100 beds
Charité Hospital Berlin ~ 3,200 beds
University Clinic Hamburg-Eppendorf ~1,370 beds
Prince Court Medical Center, Kuala Lumpur ~ 330 beds
Al Ain Hospital, Abu Dhabi ~ 450 beds
 

READ MORE ABOUT FRESENIUS VAMED >>

close
for greater efficiency - Fresenius Vamed
  • Print page
  • Save as PDF
  • Add to Cart
  • Recommend Page

Print

19. OTHER ACCRUED EXPENSES

As of December 31, other accrued expenses consisted of the following:

  2008 2007
in million €
thereof
short-term
  thereof
short-term
Personnel expenses 365 320 364 320
Invoices outstanding 137 137 101 101
Self-insurance programs 93 93 100 100
Special charge for legal matters 83 83 78 78
Bonuses and discounts 76 76 48 48
Legal matters, advisory and audit fees 40 40 50 50
Warranties and complaints 27 23 24 19
Commissions 17 17 17 17
Physician compensation 9 9 11 11
All other accrued expenses 318 288 299 271
Other accrued expenses 1,165 1,086 1,092 1,015
   

The following table shows the development of other accrued expenses in the fiscal year:

in million € As of
January 1,
2008
Foreign
currency
translation
Changes in
entities
consolidated
Ad-
ditions
Reclassifi-
cations
Utilized Re-
versed
As of
December 31,
2008
Personnel expenses 364 6 1 195 -2 -178 -21 365
Invoices outstanding 101 -4 8 106 -60 -14 137
Self-insurance programs 100 4 1 2 -14 93
Special charge for legal matters 78 5 0 0 0 0 0 83
Bonuses and discounts 48 10 66 2 -48 -2 76
Legal matters, advisory
and audit fees
50 3 15 -26 -2 40
Warranties and complaints 24 19 -1 -9 -6 27
Commissions 17 1 22 -22 -1 17
Physician compensation 11 0 0 0 -2 0 9
All other accrued expenses 299 -4 17 194 1 -152 -37 318
Total 1,092 7 41 619 -511 -83 1,165
   

Accruals for personnel expenses mainly refer to bonus, severance payments, contribution of partial retirement and holiday entitlements.

In 2001, Fresenius Medical Care recorded a US$ 258 million special charge to address legal matters relating to transactions pursuant to the Agreement and Plan of Reorganization dated as of February 4, 1996 by and between W.R. Grace & Co. and Fresenius AG (Merger), estimated liabilities and legal expenses arising in connection with the W.R. Grace & Co Chapter 11 proceedings (Grace Chapter 11 Proceedings) and the cost of resolving pending litigation and other disputes with certain commercial insurers. During the second quarter of 2003, the court supervising the Grace Chapter 11 Proceedings approved a definitive settlement agreement entered into among Fresenius Medical Care, the committee representing the asbestos creditors and W.R. Grace & Co Under the settlement agreement, Fresenius Medical Care will pay US$ 115 million (€ 83 million), without interest, upon plan confirmation (see Note 29, Commitments and contingent liabilities). With the exception of the proposed US$ 115 million settlement payment, all other matters included in the special charge have been resolved.